I think we need to be very clear that we understand that many of the PET--and I actually gave many talks last week around this--radiotracers that you're talking about are not in routine use at the moment. So, for example, estrogen-receptor imaging is not a routine test that will be done currently with technetium. So I think we need to concentrate on those techniques that we can use to replace the current technetium radiopharmaceuticals, or substitute for the current technetium radiopharmaceuticals. That's the intent of the CIHR award; that's the intent in our hospital of shifting to fluoride.
On June 18th, 2009. See this statement in context.